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Background: Substance P is an important neuropeptide released from nociceptors to mediate pain signals. We
recently revealed antinociceptive signaling by substance P in acid-sensing ion channel 3 (ASIC3)-expressing muscle
nociceptors in a mouse model of acid-induced chronic widespread pain. However, methods to specifically trigger
the substance P antinociception were still lacking.
Results: Here we show that acid could induce antinociceptive signaling via substance P release in muscle. We
prevented the intramuscular acid-induced hyperalgesia by pharmacological inhibition of ASIC3 and transient receptor
potential V1 (TRPV1). The antinociceptive effect of non-ASIC3, non-TRPV1 acid signaling lasted for 2 days. The non-ASIC3,
non-TRPV1 acid antinociception was largely abolished in mice lacking substance P. Moreover, pretreatment with
substance P in muscle mimicked the acid antinociceptive effect and prevented the hyperalgesia induced by
next-day acid injection.
Conclusions: Acid could mediate a prolonged antinociceptive signaling via the release of substance P from
muscle afferent neurons in a non-ASIC3, non-TRPV1 manner.
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Background
Substance P (SP) is a neuropeptide released from nocicep-
tors to mediate pain transmission centrally and neuro-
genic inflammation peripherally [1,2]. Our recent study
showed that release of SP from muscle nociceptive nerve
fibers was antinociceptive in a mouse model of acid-
induced chronic widespread pain [3]. The unexpected
antinociceptive role of SP was found exclusively in acid-
sensing ion channel 3 (ASIC3)-expressing muscle noci-
ceptors: SP acts on neurokinin 1 (NK1) receptors to
reduce acid-induced depolarization via activation of an
M-type potassium channel that is G protein-independent
but tyrosine kinase-dependent. The inhibitory effect of SP
could prevent the development of chronic widespread
pain induced by repeated intramuscular acid insults.* Correspondence: chih@ibms.sinica.edu.tw
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article, unless otherwise stated.Acid is effective in causing chronic muscle pain via ac-
tivation of ASIC3 or transient receptor potential V1
(TRPV1) in muscle nociceptors [4-8]. The mouse model
of acid-induced chronic widespread muscle pain was de-
veloped to mimic the clinical symptoms of fibromyalgia,
exhibiting both chronic widespread pain and autonomic
dysfunction [4,9]. In this model, 2 injections (separated
by 2 to 5 days) of pH4.0 acid saline to one side of the
gastrocnemius muscle caused bilateral, long-lasting re-
ferred hyperalgesia in mouse hind paws. The first acid
injection produces only transient hyperalgesia that di-
minished in 24 h, and the second acid injection 2 to
5 days later to the same muscle causes long-lasting hyper-
algesia that lasts for more than 4 weeks. In mice lacking
SP signaling by genetic ablation or pharmacological block-
ade in muscle, a single intramuscular acid injection is
enough to produce long-lasting hyperalgesia [3]. In con-
trast, an additional boost of SP with the second acid injec-
tion prevents the development of chronic widespread pain
in wild-type mice that received the first acid injection.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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inhibition of ASIC3 signaling might be therapeutically use-
ful, because application of an NK1 agonist prevented the de-
velopment of long-lasting hyperalgesia induced by a second
acid injection; however, the beneficial effect of endogenous
SP release was lost during the second acid challenge [3].
Here, we aimed to probe possible ways to trigger and
enhance SP analgesia in the mouse model of chronic
widespread pain.
Results
Although ASIC3 and TRPV1 play major roles in acid-
induced nociception in muscle pain models, accumulating
evidence has shown that a subset of muscle nociceptors
express other acid sensors, such as ASIC1a, ASIC1b, and
ASIC2a [10-13]. Thus, we examined whether acid had
other biological effects in muscle in a non-ASIC3, non-
TRPV1 signaling pathway. We tested this hypothesis inFigure 1 Acid-induced prolonged antinociceptive signaling in muscle
force in mice before and after intramuscular acid injection in the gastrocne
transient hyperalgesia after the first intramuscular acid injection and chroni
mix of acid saline with APETx2 and capsazepine abolished the transient hy
chronic hyperalgesia induced by the second acid injection 5 days later. (C,
antinociceptive effect lasting for 2 days, with ASIC3 and TRPV1 blocked by
day 2 could not induce any hyperalgesic effect. Black arrows indicate when m
mice received the co-injection of acid with APETx2 and capsazepine. B, baseli
compared with the response at baseline.the Sluka acid-induced chronic widespread pain model.
We mixed acid saline (pH 4.0) with APETx2 (a selective
ASIC3 antagonist) [14] and capsazepine (a selective
TRPV1 antagonist) [15] for the first intramuscular in-
jection of the dual acid-injection scheme. As expected,
the mixture of APETx2 and capsazepine abolished the
acid-induced transient hyperalgesia with the first injec-
tion; a second acid injection 5 days later induced only
transient hyperalgesia (Figure 1A,B). The second acid
injection even failed to induce transient hyperalgesia
when administered 1 or 2 days after the first injection
(Figure 1C,D). A possible explanation is that the acid
had a prolonged antinociceptive effect in muscle via
non-ASIC3, non-TRPV1 signaling in muscle afferent
neurons.
We next probed whether the prolonged antinociceptive
effect of non-ASIC3, non-TRPV1 acid signaling was medi-
ated by SP release. We examined the effect of APETx2. The withdrawal responses of mouse hind paws to a 0.2-mN bending
mius muscle. (A) In the dual acid injection scheme, mice showed
c hyperalgesia after a second acid injection spaced 5 days apart. (B) A
peralgesia with the first injection and prevented the development of
D) With the first acid injection, acid induced a prolonged
APETx2 and capsazepine, respectively, and a second acid injection at
ice received the intramuscular acid injection. Red arrows indicate when
ne on day 0; D, day; WT, wild-type mice; CZP, capsazepine. *P < 0.05
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lacking the tachykinin 1 gene (Tac1−/−; no SP and no neu-
rokinin A production). APETx2 combined with capsaze-
pine could abolish the acid-induced transient hyperalgesia
during the first injection in Tac1−/− mice as in their wild-
type littermates (Figure 2A,B). Intriguingly, Tac1−/− mice
showed acid-induced chronic hyperalgesia (for 1 week)
when the second acid injection was given the next day.
Therefore, SP may play a key role in acid-induced pro-
longed antinociception in non-ASIC3, non-TRPV1 signal-
ing in muscle afferent neurons. If so, SP alone should be
able to reproduce the prolonged antinociceptive effect in
the acid-induced chronic widespread pain model. Indeed,Figure 2 Substance P mediates the acid-induced prolonged antinocic
APETx2 and capsazepine prevented acid-induced chronic hyperalgesia in ta
the second acid injection was given the next day. (C) Pretreatment with pH
mice. (D) Pretreatment with SM-SP abolished the acid-induced transient hy
hyperalgesia induced by a second acid injection 5 days later. (E) Pretreatm
acid-induced transient and chronic hyperalgesia in the dual acid injectio
acid injection. Red arrows indicate when mice received the co-injection of ac
received a pretreatment of pH 7.4 saline 1 day before the acid injection
1 or 5 days before acid injection. B, baseline on day 0; D, day; WT, wild-ty
tachykinin 1. *P < 0.05 compared with the response at baseline.on pretreatment with an NK1-selective agonist, [Sar9,Met
(O2)
11]-substance P (SM-SP), 1 day before the acid injec-
tion, acid no longer induced hyperalgesia (Figure 2C,D).
Just like non-ASIC3, non-TRPV1 acid signaling, the SM-
SP-induced prolonged antinociceptive signaling did not last
for 5 days. Five days after pretreatment with SM-SP, dual
acid injections 5 days apart induced transient hyperalgesia
at 4 h after the first acid injection and long-lasting hyper-
algesia after the second acid injection at 5 days (Figure 2E).
Conclusions/Discussion
Although acid is an effective algogen causing pain, espe-
cially muscle pain [16,17], we report here an antinocieptiveeption in acid-induced chronic widespread pain model. (A,B)
chykinin 1-positive (Tac1+/+) mice (A) but not Tac1−/− mice (B) when
7.4 saline did not affect the acid-induced hyperalgesia in wild-type
peralgesia the next day and prevented the development of chronic
ent with SM-SP 5 days before the acid injection did not affect the
n scheme. Black arrows indicate when mice received the intramuscular
id with APETx2 and capsazepine. Green arrow indicates when mice
. Blue arrows indicate when mice received a pretreatment of SM-SP
pe mice; CZP, capsazepine; SM-SP, [Sar9,Met(O2)
11]-substance P; Tac1,
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This acid-mediated antinociceptive pathway might act via
a subset of acid-sensitive muscle afferent neurons that are
neither ASIC3- nor TRPV1-positive to release SP. This
finding expands our recent knowledge of SP antinocicep-
tive signaling, which could have a prolonged inhibitory ef-
fect, lasting for 2 days, on muscle nociceptors.
Previously, we found that SP activated M-type potassium
channels in muscle nociceptors in a G protein-independent
manner and thus inhibited the ASIC3-induced inward
current. The inhibitory effect of SP was reproduced in vivo,
with abolished acid-induced chronic widespread pain on
co-injection of SP with acid saline into the gastrocnemius
muscle [3]. In the acid-induced chronic widespread pain
model, acid signaling seems to dominantly activate ASIC3
or TRPV1 to evoke a referred hyperalgesia in mouse hind
paws and nociceptor priming [4,8]. The results of the
current study suggest that acid also activates receptors or
ion channels in muscle afferent neurons that express nei-
ther ASIC3 nor TRPV1 to elicit the release of SP and limit
the hyperalgesia to a transient phase. The possible acid
sensors might be other members of the ASIC family
(e.g., ASIC1a and ASIC2), which are also expressed in
muscle afferent neurons [12]. Alternatively, acid might
activate a group of proton-sensing G protein-coupled
receptors (e.g., G2A, GPR4, OGR1, and TDAG8) that
are functionally coupled with ASIC3 [18-20]. Future
studies should identify the molecular identity of the
antinociceptive acid sensor(s), which will shed new
insight for the development of analgesic drugs targeting
chronic widespread muscle pain, such as in fibromyalgia.
We found that muscular SP signaling, endogenously
released from muscle afferent neurons by acid challenge
or exogenously injected, could silence muscle nocicep-
tors from further firing in 2 days. How the G-protein-
independent signaling with SP antinociception could last
for 2 days remains unknown. The G protein-independent
SP/NK1 signaling in muscle nociceptors might be as com-
plicated as its G protein-dependent pathway in other cell
types [21,22]. Nevertheless, this knowledge is clinically
useful because we can then develop strategies to prevent
the development of chronic muscle pain caused by re-
peated muscle injury or ischemic insult.
Material and methods
Animals
We used male C57/BL6 mice (8 to 12 weeks old). All pro-
cedures were approved by the Institutional Animal Care
and Use Committee of Academia Sinica and followed the
Guide for the Use of Laboratory Animals (National Acad-
emy Press, Washington, DC). Mice lacking tachykinin 1,
the gene encoding SP (Tac1−/−), were generated as previ-
ously described [23]. Tac1+/+ and Tac1−/− mice were off-
spring of congenic C57BL6 Tac1+/− intercrosses.Pain behaviors
The mouse model of acid-induced chronic widespread
pain induced by repeated intramuscular acid injection
was as described [4], with modification, and described
previously [3]. Briefly, mice received an intramuscular
injection in the gastrocnemius muscle of acid containing
20 μL acid saline (pH 4.0) with or without APETx2 (20
pmol; Alomone, Jerusalem, Israel) and capsazepine (1 nmol;
Torcis, Avonmouth, UK). Mechanical hyperalgesia of hind
paws was measured by application of a 0.2-mN von Frey
filament. The experimenter conducting the von Frey test
had no information about the mouse genotypes or drug in-
jections. In some studies, mice received pretreatment with
an intramuscular injection of pH 7.4 saline or 40 μM [Sar9,
Met(O2)
11]-substance P (SM-SP; Sigma, St. Louis, MO) at
1 or 5 days before the acid injection.
Data analysis
The Mann–Whitney U test was used to compare with-
drawal responses to the von Frey filament application in
mice before acid or pH 7.4 saline injection (baseline)
and at each time after intramuscular injection of acid
(with or without drugs). P < 0.05 was considered statisti-
cally significant.
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